SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-011647
Filing Date
2021-02-25
Accepted
2021-02-25 16:21:31
Documents
14
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea136449-8k_nektartherap.htm   iXBRL 8-K 33070
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 20 ea136449ex99-1_nektartherap.htm EX-99.1 309017
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6267
  Complete submission text file 0001213900-21-011647.txt   543541

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20210225.xsd EX-101.SCH 3171
5 XBRL LABEL FILE nktr-20210225_lab.xml EX-101.LAB 34582
6 XBRL PRESENTATION FILE nktr-20210225_pre.xml EX-101.PRE 22697
7 EXTRACTED XBRL INSTANCE DOCUMENT ea136449-8k_nektartherap_htm.xml XML 3501
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 21680665
SIC: 2834 Pharmaceutical Preparations